Renalase Gene Polymorphisms in Patients With Type 2 Diabetes, Hypertension and Stroke by Buraczynska, Monika et al.
ORIGINAL PAPER
Renalase Gene Polymorphisms in Patients With Type 2 Diabetes,
Hypertension and Stroke
Monika Buraczynska • Pawel Zukowski •
Kinga Buraczynska • Slawomir Mozul •
Andrzej Ksiazek
Received: 20 April 2011/Accepted: 14 September 2011/Published online: 2 October 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Renalase is a novel, recently identiﬁed, ﬂavin
adenine dinucleotide-dependent amine oxidase. It is
secreted by the kidney and metabolizes circulating cate-
cholamines. Renalase has signiﬁcant hemodynamic effects,
therefore it is likely to participate in the regulation of
cardiovascular function.The aim of our study was to
investigate the involvement of renalase gene polymor-
phisms in hypertension in type 2 diabetes patients. A total
of 892 patients and 400 controls were genotyped with three
SNPs in the renalase gene. The C allele of rs2296545
SNP was associated with hypertension (P\0.01). For
rs2576178 SNP, frequencies in hypertensive patients dif-
fered from controls, but not from normotensive patients.
For rs10887800 SNP, the differences in the G allele fre-
quencies were observed in hypertensive patients with
stroke, with 66% of patients being GG homozygotes. To
conﬁrm observed association we later genotyped 130
stroke patients without diabetes. The OR for risk allele was
1.79 (95% CI 1.33–2.41). In conclusion, the renalase gene
polymorphism was associated with hypertension in type 2
diabetes patients. The most interesting result is a strong
association of the rs10887800 polymorphism with stroke in
patients with and without diabetes. The G allele of this
polymorphism might thus be useful in identifying diabetes
patients at increased risk of stroke.
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Introduction
About 70% of mortality in diabetic patients is secondary
to coexisting cardiovascular disease (Mazzone 2007).
Hypertension is a major risk factor for various cardio-
vascular diseases, including coronary heart disease and
stroke (Kannel 2000).Hypertension is a common comor-
bidity in individuals with type 2 diabetes and a major
risk factor for macro- and microvascular complications
(Sowers et al. 2001; Sowers 2004; Derosa et al. 2006;
Aronow 2008; Wong et al. 2010). The relationship
between diabetes and hypertension has not been com-
pletely elucidated. The manifestation and severity of
hypertension depend on inherited predisposition combined
with environmental factors. Identiﬁcation of factors for
genetic risk of hypertension is thus essential for risk
prediction of cardiovascular disease and/or diabetes.
Several genes have shown association with essential
hypertension either in the candidate gene studies or
GWAS but the results have often been discordant (Cow-
ley 2006; Sharma and McNeill 2006; Puddu et al. 2007;
Adeyemo et al. 2009).
Renalase is a novel, recently identiﬁed, ﬂavin adenine
dinucleotide-dependent amine oxidase (Xu et al. 2005).
Renalase is secreted by the kidney and metabolizes circu-
lating catecholamines. It has signiﬁcant hemodynamic
effects, therefore it is likely to participate in the regulation
of cardiovascular function. Animal studies showed a dose-
dependent reduction in blood pressure, heart rate, myo-
cardial contractility, and vascular tone (Li et al. 2008;G u
et al. 2011; Wu et al. 2011).
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esis that renalase regulates blood pressure and is important
in the pathogenesis of hypertension (Desir 2007; Li et al.
2008; Desir 2011; Wu et al. 2011).
Human renalase is encoded by a gene on chromosome 10
(10q23.33). The renalase gene, encompassing 311,000 bp,
has 10 exons (Desir 2008). It was reported to affect risk of
type 1 diabetes (Barrett et al. 2009; Reddy et al. 2011) and
considered a novel candidate gene for type 2 diabetes
(Rampersaud et al. 2007). A recently published study
reported association of the renalase gene polymorphisms
with essential hypertension (Zhao et al. 2007). The authors
examined eight single nucleotide polymorphisms (SNPs) of
the renalase gene among 1,317 hypertensive individuals and
1,269 normotensive controls from the International Col-
laborative Study of Cardiovascular Disease in Asia. Two of
the analyzed SNPs were signiﬁcantly associated with
essential hypertension. These results support the theory that
renalase plays an important role in the development and
maintenance of hypertension. If replicated, they may pro-
vide novel genetic susceptibility markers for hypertension.
The purpose of our preliminary study was to investigate
the potential involvement of the renalase gene polymor-
phisms in hypertension in type 2 diabetes patients. Later in
the study the cohort of patients with stroke but no diabetes
was included to conﬁrm observed association of the rena-
lase gene SNP with stroke. The SNPs selected for our
study are located in putative functional regions. One
SNP (rs2296545) results in an amino-acid substitution
(Asp37Glu) and might affect the function of the gene
product. The other two SNPs are at the 50 ﬂanking region
(rs2576178) and near exon/intron boundary (rs10887800)
and might affect gene regulation and expression.
Materials and Methods
Study Population and Design
The present investigation was designed to analyze the re-
nalase gene polymorphisms in type 2 diabetes (T2DM)
patients with and without hypertension. To compare the
prevalence of polymorphisms in patients with a healthy
population, we studied a control group of healthy individ-
uals. Later in the study an additional group of patients with
stroke was included to conﬁrm the observed association.
The study population (cases) consisted of 892 unrelated
T2DM patients, consecutively enrolled between January
2004 and September 2008. The recruited patients were
referred by physicians from the Departments of Internal
Diseases, Endocrinology and Nephrology and the outpa-
tient Diabetes Clinic of Medical University. They were
enrolled without selection for any complications of
diabetes or coexisting diseases. All subjects were Cauca-
sians of Polish origin. Diabetes was diagnosed according to
American Diabetes Association criteria. For the diagnosis
one or more of the following conditions were met: the
presence of classic symptoms of hyperglycemia (polyuria,
polydipsia, weight loss), fasting plasma glucose C126 mg/
dl or random plasma glucose C200 mg/dl, the use of
insulin or oral hypoglycemic agents. The mean duration of
diabetes was 12.9 years (range 8–26). It was estimated
from time of the ﬁrst symptoms attributable to the disease
or from time of ﬁrst detection of glycosuria. The mean
level of HbA1c was 8.8%. In the patient group 681 indi-
viduals (76%) were hypertensive. Hypertension was
deﬁned according to World Health Organization criteria
(WHO 1999). All patients had persistent systolic blood
pressure [140 mm Hg and diastolic blood pressure
[90 mm Hg and/or were receiving anti-hypertensive
treatment. The secondary hypertension was excluded by
clinical and laboratory examination. In the studied patient
population with long lasting T2DM, 41% had a diabetic
renal disease and almost 46% had diabetic retinopathy.
A positive family history of diabetes in ﬁrst-degree
relatives was reported by 218 patients (24%).
Glycemic control was evaluated by measuring glycated
HbA1c levels by turbidimetric inhibition immunoassay
(TINIA) using Tina-quant hemoglobin A1cII (Roche-Hit-
achi 747). All other biochemical parameters were measured
by standard laboratory procedures.
Patients with stroke but without diabetes (n = 130)
were included later in the study to conﬁrm the association
of the SNP in renalase gene with stroke, observed in dia-
betic patients. They were hospitalized in the Stroke Unit of
Department of Neurology. Among this group 112 patients
had ischemic stroke and 18 had hemorrhagic stroke.
Healthy subjects (controls) (n = 400) were normoten-
sive volunteers (mostly blood donors and hospital staff
members) with no history of diabetes or hypertension. Their
systolic and diastolic blood pressure was less than 140 and
90 mm Hg, respectively. Written informed consent was
obtained from all subjects in accordance with principles of
the Declaration of Helsinki. The protocol of the study was
approved by the institutional ethics committee.
Genotype Determination
We analyzed two SNPs that were found to be associated
with hypertension in the Asian study (Zhao et al. 2007) and
one (rs10887800) of those that were not associated, for a
potential conﬁrmation of negative result as well.
Genomic DNA was extracted from peripheral blood
leukocytes (obtained from EDTA anticoagulated blood)
using a technique from Madisen et al. (1987), with
modiﬁcations.
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(dbSNP accession numbers: rs2576178, rs10887800 and
rs2296545) were determined by the PCR–RFLP method.
The following primers were used: forrs2296545forward
50-GGAAGTCCCCGATCACGTGAC-30 and reverse 50-T
GCTGTGTGGGACAAGGCTGA-30; for rs2576178 for-
ward 50-AGCAGAGAAGCAGCTTAACCT-30 and reverse
50-TTATCTGCAAGTCAGCGTAAC-30 and for rs1088
7800 forward 50-CAGGAAAGAAAGAGTTGACAT-30
and reverse 50-AAGTTGTTCCAGCTACTGT-30 Genomic
DNA (200 ng) was ampliﬁed in a ﬁnal volume of 30 ll,
containing 10 mM TRIS pH 8.3, 50 mM KCl, 1.5 mM
MgCl2, 200 lM each dNTP, 1 lM of each primer and 2 U
Taqpolymerase(allreagentsfromMBIFermentas,St.Leon-
Rot, Germany). The initial denaturation at 95C was fol-
lowed by 35 cycles of denaturation at 94C, annealing at
60C,extensionat72C,1 min.eachandaﬁnalextensionat
72Cfor 7 min. The PCR products(10 ll) were digested for
6–10 h with 5 U of Eco81 I, Msp I and Pst I restriction
endonucleases, respectively (MBI Fermentas) at 37C.
Fragments were analyzed on 2.5% agarose gel.
The quality of genotyping was controlled by using blind
DNA duplicates for some samples (96). Also, for all SNPs,
30 samples were randomly selected for each genotype and
the PCR products were sequenced with the forward primers
by automated sequencing in CEQ 8000 Genetic Analysis
System (Beckman Coulter).
Statistical Analysis
Statistical calculations were performed using SPSS 11.0 for
Windows (SPSS, Inc., Chicago, IL, USA). For baseline
characteristicsthenormallydistributedcontinuousvariables
are presented as means ± SD. The Hardy–Weinberg equi-
librium was tested with the V
2 test. Genotype distribution
and allele frequencies were compared between groups using
a V
2 test of independence with 2 9 2 contingency and
z statistics. Student’s t test and Mann–Whitney test were
used forstatistical signiﬁcance. Where appropriate, the odds
ratios (OR) with corresponding 95% conﬁdence intervals
(CI) were calculated. An interaction of the polymorphisms
with hypertension, stroke and various risk factors was
examined with multiple logistic regression analysis. A two-
tailed type I error rate of 5% was considered statistically
signiﬁcant. Power calculations were done using on-line
available power calculator (http://calculators.stat.ucla.edu).
Results
The genotypes of three renalase gene polymorphisms:
rs2576178 (50 ﬂanking region), rs10887800 (intron 6) and
rs2296545 (exon 2) were determined in 892 patients with
type 2 diabetes, 130 patients with stroke and 400 healthy
individuals. The genotyping error rate in the total of 366
samples checked was \0.27%. The demographic and
clinical characteristics of all groups are presented in
Table 1. As expected, subjects with diabetes had a higher
mean BMI, were more likely to have a family history of
diabetes in a ﬁrst-degree relative and had a higher mean
values of total cholesterol. There were no statistically
signiﬁcant differences in demographic proﬁle between
T2DM subjects with hypertension and those without. The
mean age was 59.9 ± 16 for patients with hypertension
and 60.3 ± 18 for those without and male to female ratio
was 1.17 in both subgroups.
Genotype distribution and allele frequencies of three
renalase gene polymorphisms were compared in subgroups
of T2DM patients with and without hypertension. Geno-
typing results for the rs2296545 and rs2576178 polymor-
phisms are summarized in Table 2. The rs2296545 SNP
was inconsistent with HWE in T2DM subjects with
hypertension (P\0.0001) The frequency of the C allele of
this polymorphism was signiﬁcantly higher in diabetes
patients with hypertension than in normotensive subgroup
and healthy controls (P\0.01). Genotype distribution was
also different between patients with hypertension and
controls (P\0.001). For the rs2576178 SNP the genotype
distribution in all patient subgroups and controls was in
HWE. The genotype distribution in the entire group of
patients with diabetes was different from healthy controls,
but there was no difference between hypertensive and
normotensive patients.
Patients and controls were classiﬁed by their genotypes
of rs2296545 and rs2576178 SNPs and relationship
between clinical and biochemical parameters and genotype
was analyzed. The following parameters were examined
:age, % males, age at diagnosis, systolic and diastolic blood
pressure, BMI, HbA1c, total cholesterol, triglycerides and
creatinine. No statistically signiﬁcant associations were
observed between genotypes and studied parameters (all
p values in a range 0.092–0.873) (data not shown).
A multivariate logistic regression analysis was per-
formed with the renalase gene genotype and crucial clinical
parameters as independent variables and the hypertension
status as dependent variable. The results showed that after
confounding effects of age, gender, BMI and lipid proﬁle
were adjusted, the renalase rs2296545 genotype was sig-
niﬁcantly and independently associated with hypertension
in diabetic patients (OR 2.58, 95% CI 1.231–4.067,
P 0.0093).
The distribution of genotypes and alleles of the
rs10887800 polymorphism is shown in Table 3. This SNP
deviated slightly from HWE proportions in T2DM patients
without hypertension (P = 0.034). The frequencies of the
G allele were similar in hypertensive patients and controls
Neuromol Med (2011) 13:321–327 323
123Table 1 Demographic and clinical proﬁle of studied subjects
Variables T2DM patients Stroke patients Controls P value**
N 892 130 400
Gender (M/F) 482/410 42/88 206/194 0.12
Age at study (years) 60.3 ± 18 64.7 ± 11 53 ± 18 \0.001
Age at diabetes diagnosis (years) 47 ± 9.3 NA NA
Diabetes duration (years) 12.9 (9–26)* NA NA
Total cholesterol (mmol/l) 5.2 ± 1.19 4.9 ± 1.8 3.9 ± 1.32 \0.01
Triglycerides (mmol/l) 2.3 ± 1.52 1.9 ± 1.42 1.21 ± 0.87 \0.001
Serum creatinine (mg/dl) 3.21 ± 1.9 0.91 ± 0.4 ND \0.001
HbA1c (%) 8.8 ± 3.4 ND ND
SBP (mmHg) 151.3 ± 2.2 148.9 ± 4.3 117.6 ± 3.1 \0.001
DBP (mmHg) 91.6 ± 2.7 92.2 ± 3.8 73.4 ± 1.6 \0.001
BMI (kg/m
2) 28.9 ± 4.1 27.2 ± 4.1 25.1 ± 4.5 \0.001
Hypertension (%) 681 (76) 115 (88) 0
Stroke (%) 42 (5) 130 (100) 0
Diabetic nephropathy (%) 362 (40.6) 0 0
Diabetic retinopathy (%) 410 (46) 0 0
Family history of DM (%) 218 (24) 8 (6) 14 (3.5) \0.001
T2DM type 2 diabetes, SBP systolic blood pressure, DBP diastolic blood pressure. NA not applicable, ND not determined. Notes: For continuous
characteristics, values are presented as means ± SD. For discrete characteristics values are numbers and percentages (in parentheses). * Range.
** DM2 patients versus controls
Table 2 Distribution of rs2296545 and rs2576178 polymorphisms in diabetes patients and controls
SNP T2DM with HY
(n = 681)
T2DM no HY
(n = 211)
Controls
(n = 400)
OR (95% CI) for C allele P value* for
genetic models
Versus
controls
Versus T2DM
no HY
rs2296545
a
CC 265 (39) 59 (28) 108 (27) Codominant 0.041
CG 280 (41) 106 (50) 204 (51) Dominant 0.230
GG 136 (20) 46 (22) 88 (22) Recessive 0.036
C allele 0.59 0.53 0.52 1.32
(1.11–1.58)
1.29
(1.04–1.61)
G allele 0.41 0.47 0.48
HWE v
2 = 14.73;
P\0.0001
v
2 = 14.73;
P = 0.887
v
2 = 14.73;
P = 0.654
OR (95% CI) for G allele for
T2DM group versus controls
b
rs2576178
b
AA 272 (40) 76 (36) 188 (47) Codominant 0.057
AG 314 (46) 101 (48) 181 (45) Dominant 0.194
GG 95 (14) 34 (16) 31 (8) Recessive 0.021
A allele 0.63 0.60 0.70
G allele 0.37 0.40 0.30 1.38 (1.16–1.65)
HW v
2 = 0.08;
P = 0.777
v
2 = 0.00;
P = 0.992
v
2 = 1.95;
P = 0.162
T2DM type 2 diabetes, HY hypertension. Notes: For discrete characteristics values are numbers and percentages (in parentheses). * From v
2 test
a For T2DM with HY the power (a = 0.05) to detect association was 78% versus no HY (OR = 1.29) and 72.4% versus controls (OR = 1.32)
b For T2DM with HY the power (a = 0.05) to detect association was 76% versus controls (OR = 1.38)
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showed slightly lower frequency of this allele (0.44). The
signiﬁcant differences in the distribution of this polymor-
phism were seen in hypertensive patients with a history of
stroke. Out of 681 diabetes patients with hypertension, 41
had a history of stroke. The G allele frequency in this
subgroup was 0.80. Among174 GG homozygotes observed
in all hypertensive patients, 28 were stroke survivors.
To conﬁrm this observed association we also included in
our study a group of 130 stroke patients without diabetes.
In this group the frequency of the risk allele was 0.62. The
odds ratio (OR) for the G allele was 1.79 (95% CI
1.33–2.41). Eighty-seven percent of these patients with
stroke were G allele carriers.
The presence of the G allele did not show any statisti-
cally signiﬁcant association with gender, diabetes duration,
BMI or cholesterol.
Discussion
The renalase gene is a reasonable candidate to be poten-
tially involved in blood pressure regulation. In a large
study on the potential association of renalase gene poly-
morphisms with human hypertension eight SNPs were
examined. The results suggested that genetic variants in the
renalase gene may inﬂuence the susceptibility to essential
hypertension in the northern Han Chinese population The
authors studied common single nucleotide variations, with
minor allele frequencies (MAF) C0.05 (Zhao et al. 2007).
InourstudypatientswithT2DM,patients withstrokeand
healthy individuals were genotyped with three SNPs in the
renalase gene : rs2576178 (MAF = 0.48) and rs2296545
(MAF = 0.44) which in Zhao’s study were associated with
hypertension (Zhao et al. 2007) and in addition rs10887800.
The frequencies of genotypes and alleles for rs2296545 and
rs10887800 were similar to those observed in Zhao’s study
but different for the rs2576178 SNP. Minor allele frequen-
cies in our study were 0.48 for rs2296545 and 0.48 for
rs10887800.
We observed that the frequency of the C allele of
rs2296545 polymorphism was also higher in diabetes
patients with hypertension than in patients without hyper-
tension andcontrols.ThissuggeststhatinPolishpopulation,
atleastindiabeticpatients,theCalleleofthispolymorphism
is also associated with susceptibility to hypertension. This
polymorphism might affect the function of the gene product
but it also might be nonfunctional but in the tight linkage
disequilibrium with another functional variant. This needs
further functional studies. However, because the rs2296545
SNP shows substantial deviation from HWE estimates
(P\0.0001) in T2DM patients with hypertension, these
results should be viewed with caution. The genotyping
errors can be excluded since the quality of genotyping in our
study was carefully controlled with using blind sample
duplicates and direct sequencing. The likely reason for the
deviation from HWE may be the selection bias.
Regarding the rs2576178 polymorphism, there was no
signiﬁcant difference in the genotype/allele distribution
between hypertensive and normotensive patients. If the
effect of the G allele is small, this result might be due to the
relatively small size of our normotensive patient subgroup.
There was a signiﬁcant difference in the G allele frequency
of this SNP between our and Zhao’s studies (0.30 and 0.52,
respectively, compared to 0.356 in NCBI dbSNP), thus the
genetic heterogeneity across populations might also par-
tially explain the discrepancy between Zhao’s and our
results. The G allele and GG genotype frequencies of
Table 3 Distribution of rs10887800 polymorphism in diabetes patients, stroke patients and controls
T2DM with HY (n = 681) T2DM no HY (n = 211) Stroke (n = 130) Controls (n = 400)
rs10887800
Genotype
AA 185 (27) 73 (35) 17 (13) 115 (29)
AG 322 (47) 89 (42) 64 (49) 185 (46)
GG 174 (26) 49 (23) 49 (38) 100 (25)
Allele
A 0.51 0.56 0.38 0.52
G 0.49 0.44 0.62* 0.48
G allele carriers 496 (73) 138 (65) 113 (87) 285 (71)
HWE v
2 = 1.99; P = 0.158 v
2 = 4.46; P = 0.034 v
2 = 0.3; P = 0.583 v
2 = 2.17; P = 0.140
OR (95% CI) for G allele versus controls
1.04 (0.87–1.24) 0.941 (0.67–1.18) 1.79 (1.33–2.41) Ref.
T2DM type 2 diabetes, HY hypertension. Notes: For discrete characteristics values are numbers and percentages (in parentheses)
For stroke patients the power (a = 0.05) to detect association was 87.6% versus controls (OR = 1.79)
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patients than in controls which might suggest an associa-
tion of renalase gene SNP with diabetes itself. This would
require further studies in a larger patient population to draw
such conclusion. The association of the renalase gene locus
with type 2 diabetes was earlier observed in a genome-wide
association scan in the Amish population (Rampersaud
et al. 2007).
The rs10887800 polymorphism was not associated with
hypertension in Zhao’s study. In our study the frequencies
of the G allele were also similar in hypertensive patients
and controls. However, the signiﬁcant difference was
observed in the hypertensive diabetes patients who had a
stroke (6% of all hypertensive patients). The G allele fre-
quency in those patients was 1.63 times higher than in all
hypertensive patients and 95% of patients with stroke were
G allele carriers. To conﬁrm this association we genotyped
patients with stroke but no diabetes with this polymor-
phism. The frequency of the G allele was high in this
group, with the odds ratio for this risk allele 1.79 (95% CI
1.33–2.41). This suggests that the G allele might be a risk
factor for stroke in hypertensive individuals. The mecha-
nism of this is not clear. Stroke is a multifactorial poly-
genic disease controlled by multiple genetic and
environmental factors. Hypertension is one of important
stroke risk predictors and it contributes signiﬁcantly to the
onset of disease (Rohr et al. 1996). These two conditions
might share the same etiopathogenesis. The candidate
genes for hypertension might be involved in stroke path-
ogenesis as well but they may have different impact
depending on other, nongenetic risk factors (Matarin et al.
2010). There is a possibility that observed association of
renalase gene with stroke could be related to more severe
hypertension. However, at present there are no data
reported indicating that any particular genotypes of rena-
lase gene polymorphisms affect the severity of hyperten-
sion. In our study we did not observe association between
studied SNPs and blood pressure values in stroke patient
group. Elaborating this would require a separate study in a
larger population of stroke patients.
The results obtained in our study have to be interpreted
with caution. The renalase gene is not a typical candidate
gene in hypertension and/or cardiovascular disease. The
biological mechanisms of any association of gene variants
with those diseases are not clear at this point. In addition,
our study is a hospital-based case control study and
although the sample size is relatively large and homoge-
neous, the genotyping results should be replicated in future
large-scale studies.
In conclusion, our study is the ﬁrst published study of
the association of the renalase gene polymorphisms with
hypertension and stroke in European population. The
results demonstrate that the renalase gene polymorphism
rs2296545 is associated with hypertension in type 2 dia-
betes patients. The most interesting result is a strong
association of the rs10887800 polymorphism with stroke in
diabetes patients with hypertension and also in stroke
patients without diabetes. The G allele of this polymor-
phism might thus be useful in identifying diabetes patients
and other individuals at the risk of stroke.
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